US OptionsDetailed Quotes
NAMS250117C7500
- 17.70
- -0.10-0.56%
15min DelayTrading Dec 23 10:35 ET
17.70High17.70Low
17.70Open17.80Pre Close5 Volume30 Open Interest7.50Strike Price8.85KTurnover0.00%IV-1.95%PremiumJan 17, 2025Expiry Date18.20Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.49Leverage Ratio--Theta--Rho--Eff Leverage--Vega
NewAmsterdam Pharma Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
10
1
4
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly
$NewAmsterdam Pharma (NAMS.US)$
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significa...
$NewAmsterdam Pharma (NAMS.US)$ ⭕NewAmsterdam Pharma（NAMS）周一表示，对于家族性高胆固醇血症杂合子患者潜在降低胆固醇的药物obicetrapib的3期临床研究已达到主要终点，但是，股价却在消息发布后跌超8%，为此，找到相关本次临床相关信息以便进一步评估其下跌：
🔺obicetrapib是用于治疗低密度脂蛋白胆固醇（“LDL-C”）升高且有心血管疾病（“CVD”）风险的患者，这些患者现有疗法效果不够好或耐受性不佳
🔺本次临床试验的对象及其入选条件
Study Overview
Brief Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hyper...
🔺obicetrapib是用于治疗低密度脂蛋白胆固醇（“LDL-C”）升高且有心血管疾病（“CVD”）风险的患者，这些患者现有疗法效果不够好或耐受性不佳
🔺本次临床试验的对象及其入选条件
Study Overview
Brief Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hyper...
+2
10
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
8
3
Analysts have upgraded revenue forecasts for NewAmsterdam Pharma next year, despite slower expected growth than the industry. They also increased the price target, indicating an improved intrinsic business value.
1
$NewAmsterdam Pharma (NAMS.US)$ sold with few percentages uptrend indicator left sky 👍🏻
$NewAmsterdam Pharma (NAMS.US)$ awsome 10% up top gainer in portfolio more potential here
No comment yet
Alwayslearning5 : LOL